Bone health in advanced prostate cancer: pathophysiology and management strategies
The Oncologist · 06.08.2026 · 31 (9)
DOI: 10.1093/oncolo/oyag321 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift The Oncologist, online erschienen am 25.08.2026. Verfasst von Rana R McKay und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine and Urology, University of California San Diego, San Diego, CA 92093, United States. Hauptthemen laut MEDLINE: Bone Neoplasms, Bone Density Conservation Agents, Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant. Die Arbeit nennt 114 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, Bayer HealthCare Pharmaceuticals.
Abstract (Originalsprache)
Bone loss and bone metastases can increase morbidity and impair quality of life for patients with prostate cancer. Use of hormonal agents can compromise bone integrity from treatment initiation, and the emergence of bone metastases further increases the risk of symptomatic skeletal-related events. Management of bone health should therefore be pivotal across the prostate cancer continuum. Current guidelines recommend that all men starting or receiving androgen-deprivation therapy for prostate cancer be assessed regularly for bone loss using predictive tools such as dual-energy X-ray absorptiometry and Trabecular Bone Score. Bone health agents (BHAs) are recommended for all men with castration-resistant prostate cancer with skeletal metastases to prevent symptomatic skeletal-related events and for high-risk men receiving androgen-deprivation therapy to prevent treatment-related bone loss. Options include bisphosphonates such as zoledronic acid and alendronate and the receptor activator of nuclear factor kappa-B ligand inhibitor denosumab. Patients should be monitored for adverse effects of BHAs, such as osteonecrosis of the jaw and hypocalcemia. Alongside BHAs, there are treatment options for metastatic castration-resistant prostate cancer associated with beneficial bone-related effects, notably abiraterone acetate, enzalutamide, and radium-223. In this narrative review, we focus on how bone health management can be integrated into standard clinical practice in men with advanced prostate cancer. We also present a test-and-treatment algorithm for bone health management in men with metastatic prostate cancer. Improving treatment-related bone loss and proactively managing bone metastases should be standard practice in all men with prostate cancer to improve health outcomes and quality of life.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine and Urology, University of California San Diego, San Diego, CA 92093, United States.
- Department of Medicine, University of California San Diego, San Diego, CA 92093, United States.
- Bayer HealthCare Pharmaceuticals, Whippany, NJ 07981, United States.
- Department of Medicine and Endocrinology, David H. Koch Center for Cancer Care, Memorial Sloan Kettering Cancer Center, New York, NY 10021, United States.
ORCID-Profile: Rana R McKay, Gina Woods
Förderung
- NCI NIH HHS
- Bayer HealthCare Pharmaceuticals
Zitieren
APA
McKay, R. R., Hofflich, H., Woods, G., Andres, R., & Farooki, A. (2026). Bone health in advanced prostate cancer: pathophysiology and management strategies. The Oncologist, 31(9). https://doi.org/10.1093/oncolo/oyag321
Vancouver
McKay RR, Hofflich H, Woods G, Andres R, Farooki A. Bone health in advanced prostate cancer: pathophysiology and management strategies. The Oncologist. 2026;31(9). doi:10.1093/oncolo/oyag321
BibTeX
@article{McKay2026,
author = {McKay, Rana R and Hofflich, Heather and Woods, Gina and Andres, Richard and Farooki, Azeez},
title = {Bone health in advanced prostate cancer: pathophysiology and management strategies},
journal = {The Oncologist},
year = {2026},
volume = {31},
number = {9},
doi = {10.1093/oncolo/oyag321}
}
EUVIMED